Clearside Biomedical (CLSD) Competitors

Clearside Biomedical (NASDAQ:CLSD) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.

Does the MarketBeat Community favor CLSD or MRKR?

Clearside Biomedical received 296 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 67.52% of users gave Clearside Biomedical an outperform vote while only 63.72% of users gave Marker Therapeutics an outperform vote.

Company	Underperform	Outperform
Clearside Biomedical	Outperform Votes 368 67.52%	Underperform Votes 177 32.48%
Marker Therapeutics	Outperform Votes 72 63.72%	Underperform Votes 41 36.28%

Which has more volatility and risk, CLSD or MRKR?

Clearside Biomedical has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.

Which has preferable earnings and valuation, CLSD or MRKR?

Marker Therapeutics has lower revenue, but higher earnings than Clearside Biomedical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearside Biomedical	$8.23M	9.68	-$32.49M	-$0.45	-2.33
Marker Therapeutics	$3.31M	8.57	-$8.24M	N/A	N/A

Is CLSD or MRKR more profitable?

Marker Therapeutics has a net margin of -179.74% compared to Clearside Biomedical's net margin of -413.83%. Clearside Biomedical's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearside Biomedical	-413.83%	N/A	-92.90%
Marker Therapeutics	-179.74%	-89.63%	-71.62%

Do analysts prefer CLSD or MRKR?

Clearside Biomedical presently has a consensus price target of $5.33, suggesting a potential upside of 407.94%. Marker Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 497.48%. Given Marker Therapeutics' higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Clearside Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearside Biomedical	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Marker Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor CLSD or MRKR?

In the previous week, Clearside Biomedical had 10 more articles in the media than Marker Therapeutics. MarketBeat recorded 12 mentions for Clearside Biomedical and 2 mentions for Marker Therapeutics. Clearside Biomedical's average media sentiment score of 0.65 beat Marker Therapeutics' score of 0.45 indicating that Clearside Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clearside Biomedical	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of CLSD or MRKR?

18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 9.2% of Clearside Biomedical shares are owned by company insiders. Comparatively, 17.4% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Clearside Biomedical beats Marker Therapeutics on 9 of the 15 factors compared between the two stocks.